Join us for an in-depth discussion with neonatal experts feeding Evivo (activated B. infantis EVC001) in their NICUs
Our speakers will share:
● The unique clinical benefits and mechanism of feeding Evivo to infants in the NICU
● Published research on the strain superiority of activated B. infantis EVC001, the specific strain of bacteria used in Evivo
● Candid accounts of their experience implementing Evivo as a standard of care in their NICUs
● Clinical outcomes reported and observed with the use of Evivo
Dinner Speakers:
Mike Fitzgerald, MD
Attending Neonatologist
Medical Director, Elmhurst NICU
Co-Founder, DuPage Neonatology Associates
Dr. Fitzgerald trained at Loyola Medical Center in Chicago for pediatrics and neonatology and then went on to co-found DuPage Neonatology Associates, an academic, private practice group in Chicago. Dr. Fitzgerald continues to practice neonatology full time, has become a nationally and internationally recognized expert on infant nutrition, and is frequently asked to speak at the local, national, and international level.
Heaven Holdbrooks, RN, MSN, PNP, CNS, RNC-NIC
Clinical Nurse Specialist
Health System in Southern California
Heaven is a board-certified neonatal nurse and clinical nurse specialist working in a Level III NICU at a large healthcare system in Southern California. She has worked in the NICU for the past 10 years and is well versed in quality improvement initiatives.
Bethany Henrick, PhD
Director of Immunology & Diagnostics
Evolve BioSystems
Bethany is an immunologist with extensive experience investigating maternal and infant immunity as well as a decade of experience designing, optimizing, and bringing to market rapid point-of-care diagnostics focused on improving the lives of individuals globally. In addition to her position at Evolve, Bethany also serves as an Adjunct Assistant Professor in the Food Science and Technology Department at the University of Nebraska Lincoln. Prior to joining Evolve, she managed international, multi-discipline scientific projects at UC Davis as Associate Director of the Foods for Health Institute. Bethany received her Ph.D. in Medical Sciences, specializing in Infection and Immunity, from McMaster University.
Central precocious puberty (CPP) is the onset of development signs of sexual maturation earlier than would be expected based on population forms, typically defined as puberty onset before 8 years in girls and 9 years in boys. Early identification and treatment are critical when true precocious puberty is present. The need for timely attention to apparent premature development is augmented by the possibility that precocious puberty is the result of a tumor or other disorder. In this virtual CME-accredited satellite symposium, two experts in CPP will discuss strategies for improving early detection of this disorder by recognizing clinical signs and symptoms, review testing options for diagnosis, determine when to refer to a pediatric endocrinologist for further management, and reviewing existing and newly available treatment options for patients with CPP. Register here: https://us02web.zoom.us/webinar/register/WN_TMSGkNMNQb25ddYvefibwQ
Join us for an in-depth discussion with two Pediatric experts who will share newly published research revealing that infant gut dysbiosis is widespread in the U.S. and what this means for your infant patients, including:
● Why common conditions: colic, eczema, gassiness, fussiness, and diaper rash are signs of gut dysbiosis in infants
● How gut dysbiosis impacts the development of a healthy immune system
● How to restore beneficial B. infantis and resolve dysbiosis
● The latest peer-reviewed reported outcome data on improved symptoms after feeding activated B. infantis
Speakers:
Karl Sylvester, MD, FACS, FAAP
Professor of Pediatric Surgery
Associate Dean of Maternal Child Health Research
Stanford University
Whitney Casares, MD, MPH, FAAP
Pediatrician and AAP author
Pediatric Associates of the Northwest in Portlanda
A systemic literature review of evidence based neonatal skin care practices (2015 – current). Register here: https://waterwipes.site/symposium
Rhythm’s Genetic Obesity Learning Development (GOLD) Academy brings together healthcare providers to learn about rare genetic diseases of obesity and the role of the melanocortin-4 receptor pathway in regulating hunger, caloric intake, energy expenditure, and consequently body weight. These physician-led programs are virtual or live and focus on educational topics including distinguishing hyperphagia from other overeating behaviors and key clinical characteristics of rare genetic diseases of obesity. Please join us to learn more about why not all obesity is the same.
Continuous renal replacemtn therapy (CRRT) is a common modality for treatment of severe acute kidney injury (AKI) in children. Adult technologies routinely utilized to provide this therapy have a large extracorporeal volume. The PRIMSAFLEX HF20 filter set has a relatively low extracorporeal blood volume of 60 mL, which provides technological benefit for smaller children compated with current filter sets available in the USA.
Objective/Synopsis:
This session will review recent findings on the use of rabies immunoglobulin in pediatric patients as part of postexposure prophylaxis for prevention of rabies disease, discuss the epidemiology of adult versus pediatric patients receiving rabies immunoglobulin in the US, and highlight representative cases of patient wound patterns and treatment considerations for suspected rabies exposure.
Speakers:
[11:00-11:30]
James Linakis, MD, PhD: Provide an overview of rabies disease state and primary results of recent clinical trial results on safety, tolerability, and efficacy of rabies immunoglobulin (human rabies immune globulin (HRIG150)) when used as part of postexposure prophylaxis in pediatric patients with suspected exposure to rabies virus.
[11:30-12:00]
Nicholas W. Hobart-Porter, DO: Present case examples of pediatric patient presentations with indication for postexposure prophylaxis, and their effect on dosing and administration considerations to ensure appropriate use and protection.
[12:00-12:30]
Rita V. Burke, PhD, MPH: Present epidemiology of pediatric and adult patients that receive rabies immunoglobulin in the US, and differentiating patient characteristics associated with each population.
[12:30-1:00]
Roundtable discussion and panel Q/A
KOL 1
Overview of PH1 including prevalence
Metabolic and genetic testing in the diagnosis of PH1: Case 1 and Case 2
KOL 2
OXLUMO- a FDA-approved therapeutic for PH1
Mechanism of Action
Study design and data overview for ILLUMINATE-A and ILLUMINATE-B
Dosing
KOL 2/ KOL 3
Case 3 – show a real-world case where patient was treated with OXLUMO
Conclusions and Discussion
Panel based Q&A
Fibrodysplasia ossificans progressiva (FOP) is an inherited autosomal dominant condition that causes progressive heterotopic ossification (HO), which is the disabling conversion of connective tissue and muscle to bone. Current management strategies center around avoiding events that trigger HO, and a growing understanding of disease pathology has led to the development of targeted therapies, which are being evaluated in advanced phases of clinical trials. These investigational therapies may offer proactive treatment options that mitigate the pathology and progression of FOP. However, as an ultra-rare disease, FOP remains under- or misdiagnosed, and healthcare providers may miss distinct clinical characteristics that are highly suggestive of the disorder. Patients who lack a timely and accurate diagnosis often undergo unnecessary therapeutic interventions that may cause harm and may be precluded from accessing appropriate management. This educational activity seeks to present pediatric healthcare providers with FOP disease background and strategies to facilitate early recognition and diagnosis, as well as review the most recent clinical trial data of emerging targeted treatment strategies. https://docs.google.com/forms/d/e/1FAIpQLSfR0Cy-oa8x8fnD9mgUVR33rPU5WYw-3Hd-y6Mdru0y3VdixQ/viewform